ArticleMetabolic engineering2020
Engineering the oleaginous yeast Yarrowia lipolytica for high-level resveratrol production.
Article in Metabolic engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- Resveratrol's bibliometric and visual analysis from 2014 to 2023.Frontiers in plant science · 2024Pooled it
- Shikimate crosstalk enables record-level homogentisic acid production inSynthetic and systems biotechnology · 2026Article
- High-yield production of hydroxytyrosol through metabolic engineering ofSynthetic and systems biotechnology · 2026Article
- A Novel Strategy for Highly Efficient Heterologous Expression of Carbonic Anhydrase inInternational journal of molecular sciences · 2026Article
- Engineering yeast for sustainable bioproduction of tryptophan-derived aromatic compounds.FEMS yeast research · 2026Review
- Advanced applications of synthetic biology technology in biosynthesis of bioactive compounds from medicinal plants.Chinese herbal medicines · 2026Review
- Article
- Integrated protein and metabolic engineering enable high-yield biosynthesis of resveratrol derivatives inSynthetic and systems biotechnology · 2025Article
- Droplet based microfluidic and miniaturization at high-throughput level to screening heterologous secondary metabolites in microbes: A critical review.Biotechnology letters · 2025Review
- Article
- Combinatorial engineering pinpoints shikimate pathway bottlenecks in para-aminobenzoic acid production in Pseudomonas putida.Journal of biological engineering · 2025Article
- Coordinated synthesis of aromatic amino acid derived pigments in yeast via global transcriptional engineering.Microbial cell factories · 2025Article
- Synthetic Biology in Natural Product Biosynthesis.Chemical reviews · 2025Review
- Screening of Plant UDP-Glycosyltransferases for Betanin Production in Yeast.Applied biochemistry and biotechnology · 2025Article
- Reprogramming yeast metabolism for customized starch-rich micro-grain through low-carbon microbial manufacturing.Nature communications · 2025Article
- BAHD acyltransferase from dragon fruit enables production of phyllocactin in engineered yeast.FEMS yeast research · 2025Article
- Biotechnological Breakthroughs in Resveratrol Synthesis and Health Advancements.Current pharmaceutical biotechnology · 2025Review
- CRISPR/Cas9-mediatedHorticulture research · 2025Article
- Integrating Experimental and Computational Analyses of Yeast Protein Profiles for Optimizing the Production of High-Quality Microbial Proteins.Applied biochemistry and biotechnology · 2024Article
- Denovo Production of Resveratrol by Engineered Rice Wine StrainJournal of fungi (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resveratrol is a plant secondary metabolite with multiple health-beneficial properties. Microbial production of resveratrol in model microorganisms requires extensive engineering to reach commercially viable levels. Here, we explored the potential of the non-conventional yeast Yarrowia lipolytica to produce resveratrol and several other shikimate pathway-derived metabolites (p-coumaric acid, cis,cis-muconic acid, and salicylic acid). The Y. lipolytica strain expressing a heterologous pathway produced 52.1 ± 1.2 mg/L resveratrol in a small-scale cultivation. The titer increased to 409.0 ± 1.2 mg/L when the strain was further engineered with feedback-insensitive alleles of the key genes in the shikimate pathway and with five additional copies of the heterologous biosynthetic genes. In controlled fed-batch bioreactor, the strain produced 12.4 ± 0.3 g/L resveratrol, the highest reported titer to date for de novo resveratrol production, with a yield on glucose of 54.4 ± 1.6 mg/g and a productivity of 0.14 ± 0.01 g/L/h. The study showed that Y. lipolytica is an attractive host organism for the production of resveratrol and possibly other shikimate-pathway derived metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.